All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2020-01-06.
From the record
Cogent Biosciences, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2020-01-06) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-2% a year over 4 filed years; profitable in 0 of 4.
From the record
Cogent Biosciences, Inc.'s 4 filed years say what it did: revenue went from $8 million in fiscal 2017 to $8 million in fiscal 2020, down 2% a year; it rose in 2 of 3 years; the deepest fall was 65% from fiscal 2019 to fiscal 2020; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 4.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Cogent Biosciences, Inc.'s shareholder treatment is put at 4.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 42% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -52%: lost 52¢ per shareholder dollar. Leverage 32%: owes 32¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Cogent Biosciences, Inc. lost about 52 cents for every dollar of shareholders' money. Leverage: it owed about 32 cents per dollar of assets, and net share issuance: its share count grew 24.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 35% of 315 in its family; net margin -950.4%.
From the record
Cogent Biosciences, Inc.'s standing among 315 graded names in its industry family: revenue of $8 million in fiscal 2020 ranks in the bottom 40% by size; a net margin of -950.4% ranks in the bottom 31%; revenue growth of -2% a year over the last 3 filed years ranks in the bottom 34% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 26% of 315 in its family for leadership; chief executive since 2020.
From the record
Cogent Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Robbins, Andrew R (President and CEO, as filed), filing under that title since 2020-10-27, 6 years (top 40% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 6.3 years (top 36%); no officer or director change was reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 2.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Cogent Biosciences, Inc.'s room to expand is put at 2.5 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 25% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 47% of 306 in its family for growth drivers.
From the record
Cogent Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2020: revenue grew -2% a year over the last three filed years against -2% over all 4, speeding up (top 40% of its family); the newest year grew -64.9% (bottom 12%); research spending grew 30.4% a year (top 14%); capital spending grew -39% a year (bottom 30%) (its annual reports). Cogent Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 11% of 233 in its family for expectations against reality.
From the record
Cogent Biosciences, Inc.'s newest year against its own record: revenue of $8 million in fiscal 2020 came in 78.7% below the $37 million its prior three years' pace pointed to (bottom 10% of its family); net income of $75 million against a prior three-year average of $31 million (bottom 11%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 13%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made